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Dystrophin deficiency causes Duchenne muscular dystrophy
(DMD) in humans, an inherited and progressive disease of striated
muscle deterioration that frequently involves pronounced cardio-
myopathy1. Heart failure is the second leading cause of fatalities in
DMD1,2. Progress towards defining the molecular basis of disease
in DMD has mostly come from studies on skeletal muscle, with
comparatively little attention directed to cardiac muscle. The
pathophysiological mechanisms involved in cardiac myocytes
may differ significantly from skeletal myofibres; this is under-
scored by the presence of significant cardiac disease in patients
with truncated or reduced levels of dystrophin but without
skeletal muscle disease3. Here we show that intact, isolated
dystrophin-deficient cardiac myocytes have reduced compliance
and increased susceptibility to stretch-mediated calcium overload,
leading to cell contracture and death, and that application of the
membrane sealant poloxamer 188 corrects these defects in vitro.
In vivo administration of poloxamer 188 to dystrophic mice
instantly improved ventricular geometry and blocked the
development of acute cardiac failure during a dobutamine-
mediated stress protocol. Once issues relating to optimal dosing
and long-term effects of poloxamer 188 in humans have been
resolved, chemical-based membrane sealants could represent a
new therapeutic approach for preventing or reversing the pro-
gression of cardiomyopathy and heart failure in muscular
dystrophy.
It is unknown whether dystrophin deficiency directly causes
altered force transmission and/or membrane fragility in cardiac
muscle at the single myocyte level. Here we used a unique micro-
carbon fibre technique (Supplementary Fig. 1 and Video 1) that
enables the simultaneous assessment of force and intracellular
calcium concentrations of isolated, membrane-intact myocytes
under physiologically relevant mechanical loading. Single, mem-
brane-intact adult cardiac myocytes from dystrophin-deficient mice
(mdx, also known as Dmdmdx) and control mice were passively
stretched (1-s duration) over a physiologically relevant range of
sarcomere lengths (1.75–2.20 mm; ref. 4), and passive tension and
intracellular calcium concentrations ([Ca2þ ]i) were recorded.
Figure 1a shows photomicrographs of control and mdx myocytes
at different stages of the stretch protocol. In Fig. 1b, representative
simultaneous recordings of length, tension and Fura-2 ratio of single
cardiac myocytes from a control and mdx mouse are shown. The
traces on the left are the active twitch tension and calcium transient
during an electrically stimulated isometric contraction at a resting
sarcomere length of 1.75–1.80 mm. Remaining traces are tension and
calcium recordings during passive stretching of the myocyte from a
resting sarcomere length of 1.75 mm (0% stretch) to a physiologically
relevant diastolic sarcomere length of 2.00–2.20 mm (20% stretch).
Peak isometric twitch tension is not different between control and
mdx myocytes (3.6 ^ 0.7 and 4.4 ^ 0.8mNmm2 2, respectively;
mean ^ s.e.m; P ¼ 0.47), indicating that excitation–contraction
coupling and force generation/transmission are normal in mdx
myocytes. However, dystrophin deficiency did have significant effects
on passive physiological stretches in myocyte sarcomere length
(Fig. 1b). With passive excursions from resting sarcomere lengths
of 1.80 mm to longer sarcomere lengths, mdx myocytes developed
significantly increased tension compared with control myocytes
(Fig. 2a). This is in contrast to previous studies on skeletal myotubes,
where dystrophic muscles were found to be more compliant than
controlmuscles5. Stretches to sarcomere lengths greater than 2.10mm
resulted in mdx myocytes becoming unstable, with increased
[Ca2þ]i, fibrillations, eventual calcium overload and subsequent
contracture and myocyte death (Fig. 1 and Supplementary Video 2).
Reducing extracellular [Ca2þ ] from 1.8 to 0.2mM shifted the
tension–extension curves rightward, permitting stretches of up to
2.30 mm in both mdx and control myocytes (data not shown). This
highlights a role for extracellular calcium in mediating the reduced
compliance of mdx myocytes.
These results establish a primary defect in cell compliance in single,
isolated mdx myocytes, which show increased susceptibility to
stretch-mediated membrane instability and calcium-dependent
hyper-contracture. We next tested whether a chemical-based mem-
brane repair approach would have efficacy in isolatedmdxmyocytes.
The nonionic triblock co-polymer poloxamer 188, poly(ethylene
oxide)80-poly(propylene oxide)27-poly(ethylene oxide)80 (molecular
mass ,8.4 kDa), which has previously been shown to insert into
artificial lipid monolayers and repair damaged biological mem-
branes6,7, was assessed for its ability to stabilize mdx myocyte
membranes during physiological loading conditions in vitro
(Fig. 2a). Within the physiologically relevant sarcomere length
range of 1.80–2.20 mm, 150 mM P188 (ref. 8) fully restored mdx
myocyte compliance and [Ca2þ]i to control levels (Fig. 2). This dose
of P188 was shown to be effective in protecting skeletal muscle from
electrocution damage8. P188 also significantly improved twitch
tension performance after a lengthening contraction (Supplementary
Fig. 2). P188 had no effect on control C57BL/10 myocyte compliance
within this sarcomere length range (P ¼ 0.49 at 2.0 mm and P ¼ 0.58
at 2.1 mm; Fig. 2a).
The increase in [Ca2þ]i resulting from passive stretch is signifi-
cantly greater in mdx myocytes, and this is corrected by P188
(Fig. 2b). To further address the mechanism of calcium entry,
myocytes were treated with the L-type Ca2þ channel blocker nifedi-
pine. In contrast to P188, heightened [Ca2þ]i upon stretch was not
blocked by nifedipine (Fig. 2b), suggesting that elevated [Ca2þ]i may
arise from channels that are not sensitive to dihydropyridine (DHP).
Calcium leak channels are another possible pathway of calcium entry,
but are not activated by stretch9. The most likely mechanism of
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calcium entry is through small tears in the membrane that
are prevented by P188 in mdx myocytes. In additional experiments,
a lower concentration of P188 (60 mM), previously shown to
enhance membrane resealing in toxin-poisoned fibroblasts10, signifi-
cantly improved mdx myocyte stability during passive stretch
(Fig. 2c).
To test directly whether myocyte stretching causes membrane
damage in mdx myocytes, the styryl dye FM1-43 was used. This
compound is impermeable to intact cell membranes, and specifically
fluoresces when incorporated into the lipidic environment of
cellular membranes. FM1-43 has been used to demonstrate mem-
brane disruption/repair in a range of cell systems10, including
dysferlin-deficient skeletal muscle fibres11. We subjected single
cardiac myocytes to a single stretch of 20% in the presence of
2.5 mM FM 1-43 (Fig. 2d). Control C57BL/10 myocytes were
mechanically stable after stretch, with no change in FM1-43 fluores-
cence. In contrast, mdx myocytes became unstable after stretch,
showing fibrillations (Supplementary Video 3) but not cell contrac-
ture (Fig. 1a, label h), and showing a concurrent steady increase in
FM1-43 fluorescence. Stretch-mediated mdx myocyte instability/
fibrillation and elevated FM 1-43 fluorescence were completely
blocked by P188. We hypothesize that a ,20% stretch causes
instability of the mdx myocyte, allowing transmembrane influx of
Ca2þ that triggers cycles of myocyte fibrillations, which in turn
create more membrane instability. We interpret the steady increase
in FM1-43 fluorescence after the triggering stretch as the accumu-
lation of dye incorporated into the plasma membrane owing to
continuous sarcolemmal disruptions of the fibrillating myocyte.
The time course of FM1-43 fluorescence in mdx myocytes after
stretch differs somewhat from the biphasic increase in fluorescence
observed in skeletal muscles after a single laser-generated pore in
the membrane11. The type of inciting damage (laser focal point
damage in skeletal muscle versus stretch of entire cardiac myocyte
in this study) and differences in calcium handling between cardiac
and skeletal muscles (calcium-induced calcium release being
significantly more prominent in cardiac than skeletal muscle)
probably account for the differing kinetics of FM1-43 observed
here. We also found that stretching mdx myocytes by more than
20% could cause fibrillations and elevated FM1-43 fluorescence
even in the presence of P188, indicating that the fluorescence
properties of FM1-43 are not altered by P188. From these results
we conclude that P188 enhances sealing of the mdx plasma
membrane sufficiently to prevent the initial stretch-induced injury
from causing cycles of membrane de-stabilization, Ca2þ entry and
fibrillation.
We next determined whether the cellular effects of P188 in
preventing stretch-induced membrane damage in mdx cardiac myo-
cytes would translate to preventing cardiac dysfunction in mdxmice
in vivo. Baseline left ventricular haemodynamic performance was
depressed in mdx mice, including reduced left ventricular end-
diastolic volume (LVEDV) (Fig. 3 and Supplementary Table 1).
Pre-treatment with P188 by intravenous infusion increased LVEDV
to levels seen in control hearts.We hypothesize that the lower LVEDV
inmdx hearts is an organ-level manifestation of the membrane defect
observed in single isolated myocytes, and that the acute rescue of
LVEDV by P188 in themdx heart is a direct effect of restoring normal
compliance in single mdx cardiac myocytes (Fig. 2). The haemo-
dynamic parameters (Supplementary Table 1) indicate that the
primary effect of acute P188 administration is to restore end-
diastolic volumes without significantly changing end-diastolic
pressure or other parameters, consistent with a role for P188 in
improving the compliance of the mdx cardiac myocytes in vitro
(Fig. 2).
Acute cardiomyopathy and heart failure can be induced by
cardiovascular stressors in mdx mice12. We therefore tested whether
an acute dobutamine stress challenge in vivo could cause acute
cardiac failure, and whether this phenotype could be blocked by
P188. Untreated mdx mice had a very attenuated response to
dobutamine infusion (data not shown) and a significant incidence
of acute cardiac failure (Fig. 3c) during the 30-min stress-test regime,
whereas control mice responded robustly to dobutamine infusion
and did not develop acute heart failure. Pre-treatment of mdx mice
by intravenous infusion of P188 immediately improved the haemo-
dynamic response to dobutamine infusion (data not shown) and
conferred protection from dobutamine-induced acute heart failure
in vivo (P ¼ 0.005, Fig. 3c).
Collectively, these findings demonstrate that in dystrophin-
Figure 1 | Active and passive tension and [Ca21]i in single cardiac
myocytes from control and mdx mice. Representative recordings from
control (left panels) and mdx myocytes (right panels). a, Photomicrographs
of single myocytes before (a, e), during (b, f), immediately after (c, g) and
about 40 s after (d, h) a single passive stretch. Scale bar, 20 mm. b, Top traces
show changes in myocyte length, starting at resting sarcomere lengths of
1.75–1.80mm (0% stretch; isometric twitch) and extending to 2.1 mm (20%
stretch and beyond). Traces marked a–h correspond to the sequence of cell
stretch (a–h) shown in a. Middle traces show tension recordings in response
to stretch. Bottom traces are [Ca2þ]i (Fura2 ratios) during stretches.
Leftmost traces are active isometric twitches. Passive recordings are in the
absence of electrical stimulus. In mdx mice, myocytes became unstable after
stretch (f) and return to rest length (g), with massive increase in [Ca2þ]i,
hyper-contracture and death (h).
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deficient hearts, abnormal stretch-induced increases in [Ca2þ]i result
in decreased compliance at the cellular level and lower diastolic
volume in vivo. The ability of the membrane sealant P188 to correct
these abnormalities suggests that the calcium influx results from a
loss of membrane integrity. Endogenous mechanisms of membrane
repair have recently been investigated in dysferlin-deficient dys-
trophic skeletal muscles11, and some of these repair mechanisms
are elevated as part of the compensatory response in skeletal muscles
ofmdxmice13. It is reasonable to assume that similar mechanisms are
present within the cardiomyocytes, but that these are not sufficient
to redress membrane instability, particularly under heightened
mechanical stress.
Current therapeutic strategies for Duchenne muscular dystrophy
are focused on the expression of dystrophin (through exon skipping
or viral transduction of truncated dystrophin) or other genes (for
example, utrophin or dysferlin) that limit the consequences of
dystrophin deficiency14–17. The present results suggest a compara-
tively simple, chemical-based alternative involving membrane stabil-
ization and/or repair by intravenous administration of P188. As
shown here in this animal model of DMD, P188 can have immediate
beneficial haemodynamic effects under basal conditions, and may
prevent myocardial damage under acute stress conditions, for
example during surgery in DMD patients. Currently, P188 is in
phase III clinical trials for the treatment of vaso-occlusive crises in
sickle-cell anaemia patients, having recently demonstrated the safety
and non-toxicity of P188 for short-term (24-h) use in humans18.
Unlike the episodic course of sickle-cell anaemia, DMD is a pro-
gressive disease, and effective P188 therapy would probably require
chronic intravascular administration. Long-term effects of this
sealant are unclear at present and would have to be validated in
large-animal models of muscular dystrophy. In one safety study
designed for 72 h the highest dose tested was terminated early
because of adverse affects (primarily muscle pain) in healthy volun-
teers, indicating that high doses may be too toxic for long-term use19.
Human studies will be required to fully address the optimal dose,
route and duration (acute and chronic) for delivery of chemical
membrane sealants. If issues of dosing and long-term safety can be
addressed, our results indicate that membrane-sealing poloxamers
could represent a new class of therapeutic agents for preventing or
limiting progressive damage to the hearts of DMD patients, and
might also have benefits in other cardiomyopathies associated with
defects in the dystrophin glycoprotein complex20.
METHODS
Animals. Control (C57BL/10 SnJ) and mdx (C57BL/10 ScSn-mdx) mice
obtained from Jackson Laboratories were maintained in barrier isolation
facilities at the University of Michigan. The procedures used in this study were
approved by the University of Michigan Committee on the Use and Care of
Animals.
Measurements of cardiac myocyte length, tension and [Ca21]i. Methods for
isolating mouse adult cardiac myocytes were as previously reported21. Isolated
single myocytes were transferred to an experimental chamber containing a
silicon-coated glass bottom and platinum electrodes mounted on the sides to
electrically stimulate themyocytes. The chamber wasmounted on the stage of an
inverted microscope (Nikon TE300, £ 40 objective) and kept at 37 8C with a
thermoelectric device. The system for measuring length, tension and [Ca2þ]i in
membrane-intact cardiac myocytes was developed from a previously reported
method22, using a pair of microcarbon fibres. One fibre was connected to a
sensitive force transducer system (200mVmg21, Aurora Scientific) and the
other was connected to a piezoelectric translator (P-173, PI Polytec) to control
Figure 2 | Effects of P188 on passive tension and [Ca21]i during sarcomere
length stretch in control and mdx single cardiac myocytes. a, Effects of
P188 on passive tension–extension relationships. Mdx myocytes have
significantly higher passive tension than control (C57BL/10) myocytes
(asterisk, P ¼ 0.038 and P ¼ 0.031 at sarcomere lengths 2.0 and 2.1mm,
respectively). Treatment with P188 significantly reduces tension compared
with untreated mdx myocytes (hash symbol, P ¼ 0.021 and P ¼ 0.040 at
sarcomere lengths 2.0 and 2.1mm, respectively). b, Summary of the effects of
P188 and nifedipine on [Ca2þ]i in myocytes upon sarcomere length stretch to
2.1mm (n ¼ 7). Asterisks indicate mdx greater than control myocytes
(P ¼ 0.008 in untreated myocytes, P ¼ 0.32 in P188-treated myocytes and
P ¼ 0.044 in nifedipine-treated myocytes). c, Maximum tolerated sarcomere
length stretch in mdx myocytes. Maximum tolerated sarcomere length is
defined as the maximum length at which the myocyte is stable and fibrillations
(Supplementary Video 3) are absent. Asterisk indicates mdx less than all
groups (P , 0.01); hash denotesmdx þ 60mM P188 different from all groups
(P , 0.05). Number of myocytes, n ¼ 7 (control), 7 (mdx), 8 (mdx þ 60mM
P188), 7 (mdx þ 150mM P188). d, FM 1-43 fluorescence after a single stretch
in single cardiac myocytes. Summary of FM 1-43 fluorescence over time after a
20% stretch (arrow), showing mean change in voltage from baseline at the
beginning of the stretch; number of myocytes, n ¼ 7 (control), 6 (mdx), 7
(mdx þ 150mM P188). For all graphs, data represent mean ^ s.e.m.
NATURE|Vol 436|18 August 2005 LETTERS
1027
© 2005 Nature Publishing Group 
 
myocyte length. The carbon fibres used in this studywere rigid (40-mmdiameter;
0.02mN21 compliance) and not altered by the active and passive tensions
produced by single cardiac myocytes. Tension signal from the force transducer
and length signal applied to the piezoelectric translator were recorded at 1,000-
Hz sampling rate with an analogue-to-digital recording system (Accura 100,
Nicolet). Video recordings of the cardiac myocytes were digitized to measure
cell extension and sarcomere length via images on a computer screen. For
measurement of [Ca2þ]i, myocytes were incubated with 5 mM Fura-2-acetoxy-
methyl (AM) ester (Molecular Probes) and 0.02% Pluronic F127 (Molecular
Probes) for 4min at 37 8C. Fura-2 excitation was sampled at 100Hz using a
microscope-based fluorescence spectrometer (Photon Technology Inter-
national). [Ca2þ]i was determined using a previously established method
23
after subtracting background fluorescence intensity. We investigated the effect
of P188 (150 mM in extracellular buffer unless otherwise stated)8 and
nifedipine (1mM) on passive tension–extension characteristics and [Ca]i of
control and mdx single cardiac myocytes. In another procedure, cardiac
myocytes were stretched during the rising phase of twitch tension (lengthen-
ing contraction). Upon restoring sarcomere length, isometric twitch tension
was again measured (post-stretch) and compared with pre-stretch twitch
tension.
Membrane injury assay (FM 1-43 study). Single cardiac myocytes were
stretched twice with 20% extension (1-s duration) of resting cell length (this
extension is less than the critical level of stretch that results in contracture of
mdx cardiac myocytes) in HEPES-tyrode solution containing 1.8mM Ca2þ
and 2.5 mM FM1-43 dye (Molecular Probes). In the initial stretch we
confirmed the extension, and at the beginning of the second stretch (t ¼ 0)
we measured voltage output from a photomultiplier (PTi, Monmouth Junc-
tion) for 480 s, representing fluorescence intensity of a 15 £ 50-mm area on the
myocytes.
Cardiac haemodynamics in vivo.Murine pressure–volume loops were acquired
by previously described methods24. Briefly, anaesthetized mice were ventilated
with 2% isoflourane and 98% oxygen. A thoracotomy and pericardiotomy
were performed, and a pressure–volume catheter was inserted into the left
ventricle via an apical stab. Before catheter insertion, mice received an
intravenous infusion of ,150ml of 10% human albumin with and without
P188, at a rate of ,200 ml kg2 1min21. After the collection of baseline
haemodynamic data, dobutamine was infused at a dose of 42 mg kg21min21
(ref. 25). The dose of P188 (460mg kg21) was shown to be effective at
mitigating skeletal muscle damage following electrocution7. Acute cardiac
failure was defined as a drop in left ventricular systolic pressure below
60mmHg, as below this level, rapid decompensation and death were frequent
occurrences. Following the 30-min dobutamine challenge or the development
of acute cardiac failure, volume measurements were calibrated as previously
described24.
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